Use of peptide-based inhibitors of the stat3-il10 pathway for treating bacterial infection and granulomatous disease
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Servic, Colorado State University Research Foundation
InventorsNadya I. Tarasova, Mercedes Gonzalez-Juarrero
Life of this patent
Estimating the term…
Abstract
The invention provides a method of treating pathogenic bacterial infection (e.g., tuberculosis infection) in an animal comprising administering a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal. The invention also provides methods of treating chronic granulomatous disease and Wegener's granulomatosis in an animal comprising administering a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal.
Claims32
A method of treating an infection of Mycobacteriaceae sp. in an animal in need thereof, comprising administering a therapeutically effective amount of a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal, thereby treating the infection in the animal.
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a disease selected from tuberculosis, Wegener's granulomatosis, and chronic granulomatous disease in an animal in need thereof, comprising administering a therapeutically effective amount of a peptide-based inhibitor of the STAT3-IL10 pathway or a nucleic acid encoding the peptide-based inhibitor to the animal, thereby treating the disease in the animal.
Dependencies are inferred from the claim text.